U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07527767) titled 'Secondary Use of PARALLEL-HF Data' on April 07.

Brief Summary: This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to assess the effect of sacubitril valsartan at a target dose of 200 mg b.i.d. and enalapril 10 mg b.i.d. on cardiovascular (CV) mortality and morbidity in Japanese HF patients with reduced ejection fraction.

Study Start Date: July 27, 2022

Study Type: OBSERVATIONAL

Condition: Chronic Heart Failure and Reduced Ejection Fract...